Inside Information
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that the 2026 full-year financial outlook has been upgraded reflecting a strong growth momentum in tablet sales across regions.
- Revenue is now expected to grow by 16-17% in local currencies (previously 14-16% growth) based on growth in all sales regions and product lines with tablets as the key growth driver.
- The EBIT margin is now expected at around 27% (previously 26%), mainly reflecting operating leverage from the higher revenue outlook.
ALK will release its Q3 2026 report on 17 November 2026.
ALK-Abelló A/S
For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Maiken Riise Andersen, tel. +45 5054 1434
This announcement contains inside information. This is information that ALK-Abelló A/S is obliged to make public pursuant to the EU Market Abuse Regulation.
About ALK
ALK is a global specialty pharmaceutical company focused on allergy. ALK’s activities cover the entire value chain of developing, sourcing, producing, and marketing a diversified portfolio of products for diagnosing and treating respiratory allergies and severe allergic reactions (anaphylaxis) in both children and adults. Headquartered in Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen (Nasdaq: ALK B). Visit us at www.alk.net.
Attachment
